Table 1.
Basic characteristics of included studies
| First Author | Year | Sample Size (Intervention/Control) | Mean Age (years) | % Male | ACS Subtype | Intervention | Duration |
|---|---|---|---|---|---|---|---|
| Nicholls SJ [14] | 2022 | 80/81 | 62.3 | 75% | NSTEMI | Evolocumab 420 mg monthly | 12 months |
| Koskinas KC [15] | 2019 | 155/153 | 59.8 | 73% | ACS (unspecified) | Evolocumab 420 mg once | 8 weeks |
| Hao Y [16] | 2022 | 68/68 | 61.1 | 71% | ACS + PCI | Evolocumab 140 mg q2w | 12 weeks |
| Furtado RHM [17] | 2022 | 17,073 | 63.9 | 68% | Stable CAD (prior PCI) | Evolocumab | Median 2.2 yrs |
| Nicholls SJ [18] | 2016 | 484/484 | 58.2 | 82% | Stable CAD | Evolocumab 420 mg monthly | 76 weeks |
| Schwartz GG [19] | 2018 | 9,462/9,462 | 62.7 | 76% | Recent ACS | Alirocumab 75 mg q2w | Median 2.8 yrs |
| Mehta SR [20] | 2022 | 38/30 | 60.4 | 80% | STEMI | Alirocumab 150 mg x3 doses | 4 weeks |
| Leucker TM [21] | 2020 | 28/29 | 58.5 | 74% | NSTEMI | Evolocumab 420 mg once | 7 days |
| Räber L [22] | 2022 | 148/152 | 60.8 | 85% | AMI + PCI | Alirocumab 150 mg q2w | 12 months |
Nore: The included studies were categorized based on the type of lipid-lowering intervention. Evolocumab was the intervention in six trials: Nicholls SJ [14], Koskinas KC [15], Hao Y [16], Furtado RHM [17], Nicholls SJ [18], and Leucker TM [21]. Alirocumab was used in three trials: Schwartz GG [19], Mehta SR [20], and Räber L [22]. All studies included a placebo or standard care control arm, allowing for consistent comparison across interventions